Media

Full year results for the year ended 31 July 2016

C4X Discovery Holdings plc

("C4XD" or the "Company")

Full year results for the year ended 31 July 2016

6 January 2017 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its full year results for the year ended 31 July 2016.

Monday, 19 December 2016

Notice of Results

C4X Discovery Holdings plc

("C4XD" or the "Company")

Notice of Results

19 December, 2016 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, will be announcing its full year results for the year ended 31 July 2016 on Friday 6 January 2017.

Dr Clive Dix, Chief Executive Officer, and Brad Hoy, Chief Financial Officer, will host a conference call for analysts at 14.00 GMT on the day of the results. Presentation slides will be made available on the Company website before the call.

This announcement contains inside information

C4X Discovery Holdings plc
("C4XD" or the "Company")

22 November, 2016 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Brad Hoy, Chief Financial Officer (CFO), and Dr Craig Fox, Chief Scientific Officer (CSO), will join the Board of Directors with immediate effect. In addition, Brad Hoy has been appointed permanent CFO today following a period as interim CFO.

This announcement contains inside information

C4X Discovery Holdings plc
("C4XD" or the "Company")

C4X Discovery builds on previous agreement with Evotec on broad, innovative drug discovery portfolio

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that the Company has entered into a multi-target, risk-sharing alliance ("the Agreement") with Evotec AG ("Evotec"), a leading drug discovery alliance and development partnership company. The new Agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development, with the initial programmes targeted towards the treatment of cancer and autoimmune diseases.

Monday, 26 September 2016

Result of General Meeting

This announcement contains inside information

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.

As a result, the placing announced on 6 September 2016 of 4,901,961 new ordinary shares at 102 pence per ordinary share to raise £5.0 million, is conditional only on Admission which is expected to take place on 27 September 2016.

Tuesday, 06 September 2016

C4X Discovery £5 Million Fundraise

This announcement contains inside information

£5.0 Million Fundraise through the conditional Placing of 4,901,961 new Ordinary Shares at a price of 102 pence per Ordinary Share and Notice of General Meeting

Calculus Capital Limited and Polar Capital LLP to join share register

C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that it has raised £5.0 million before expenses (the "Placing") via a conditional placing of 4,901,961 new ordinary shares (the "Placing Shares") to current and new investors, through Zeus Capital as nominated adviser and broker to the Company, at a placing price of 102p (the “Placing Price”) per ordinary share.

This announcement contains inside information

Proprietary platform technology further augments C4X Discovery’s drug discovery engine

12th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the "Molplex Technologies").

~ Rapid progress with drug discovery portfolio and ground-breaking findings in inflammation and neurodegeneration ~

4th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the identification of multiple new drug targets in the areas of inflammation and neurodegeneration.